MA39856A - Promédicaments d'acide succinique pour augmenter la production d'atp - Google Patents

Promédicaments d'acide succinique pour augmenter la production d'atp

Info

Publication number
MA39856A
MA39856A MA039856A MA39856A MA39856A MA 39856 A MA39856 A MA 39856A MA 039856 A MA039856 A MA 039856A MA 39856 A MA39856 A MA 39856A MA 39856 A MA39856 A MA 39856A
Authority
MA
Morocco
Prior art keywords
permeable
cell
atp
prodrugs
succinates
Prior art date
Application number
MA039856A
Other languages
English (en)
Inventor
Karl Henrik Johannes Ehinger
Eskil Elmér
Magnus Joakim Hansson
Steven Moss
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MA39856A publication Critical patent/MA39856A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/40—Succinic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/18—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/06—1,3-Dioxepines; Hydrogenated 1,3-dioxepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Cosmetics (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux succinates pénétrant dans les cellules et de nouveaux précurseurs de succinate pénétrant dans les cellules visant à augmenter la production d'atp dans les mitochondries. La majeure partie de l'atp produit et utilisé dans la cellule eucaryote est issue de la phosphorylation oxydative mitochondriale, un procédé dans lequel des électrons à haute énergie sont fournis par le cycle de krebs. Les intermédiaires du cycle de krebs ne pénètrent pas tous facilement dans la membrane cellulaire, l'un d'eux étant du succinate. L'utilisation des nouveaux succinates pénétrant dans les cellules est envisagée pour permettre le passage à travers la membrane cellulaire et, par conséquent, les succinates pénétrant dans les cellules peuvent être utilisés pour améliorer la production d'atp mitochondriale.
MA039856A 2014-04-08 2015-04-08 Promédicaments d'acide succinique pour augmenter la production d'atp MA39856A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201470187 2014-04-08

Publications (1)

Publication Number Publication Date
MA39856A true MA39856A (fr) 2017-02-15

Family

ID=58762731

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039856A MA39856A (fr) 2014-04-08 2015-04-08 Promédicaments d'acide succinique pour augmenter la production d'atp

Country Status (14)

Country Link
US (1) US20170105960A1 (fr)
EP (1) EP3129364A1 (fr)
JP (1) JP2017518960A (fr)
KR (1) KR20160143731A (fr)
CN (1) CN106458839A (fr)
AU (1) AU2015243345A1 (fr)
CA (1) CA2944560A1 (fr)
EA (1) EA201692018A1 (fr)
IL (1) IL247903A0 (fr)
MA (1) MA39856A (fr)
MX (1) MX2016012752A (fr)
SG (1) SG11201607903UA (fr)
WO (1) WO2015155230A1 (fr)
ZA (1) ZA201606609B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129016B1 (fr) 2014-04-08 2018-06-06 Neurovive Pharmaceutical AB Nouveaux composés de succinate perméables à travers les cellules
US10307389B2 (en) 2014-04-08 2019-06-04 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
CN115957294A (zh) * 2015-05-28 2023-04-14 贝勒医学院 补充n-乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果
WO2017060418A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées aux mitochondries
WO2017060422A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des troubles mitochondriaux
KR20220139426A (ko) * 2016-03-31 2022-10-14 버클리 라잇츠, 인크. 핵산 안정화 시약, 키트들, 및 그 이용 방법들
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
WO2020077106A1 (fr) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Compositions et procédés de traitement et de prévention de la neuropathie optique héréditaire de leber
CN112899328B (zh) * 2021-04-23 2023-06-02 南京同凯兆业生物技术有限责任公司 一种利用酵母全细胞催化合成三磷酸腺苷的方法
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724652B1 (fr) 1994-09-15 1996-12-27 Oreal Utilisation de derives de dehydroalanines pour proteger la peau, les muqueuses et/ou les cheveux du stress oxydant.
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
JP2014024772A (ja) * 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
ES2661009T3 (es) * 2012-10-05 2018-03-27 Neurovive Pharmaceutical Ab Succinatos protegidos para mejorar la producción de ATP mitocondrial
EP3129016B1 (fr) * 2014-04-08 2018-06-06 Neurovive Pharmaceutical AB Nouveaux composés de succinate perméables à travers les cellules

Also Published As

Publication number Publication date
ZA201606609B (en) 2018-05-30
EP3129364A1 (fr) 2017-02-15
MX2016012752A (es) 2016-12-12
JP2017518960A (ja) 2017-07-13
CN106458839A (zh) 2017-02-22
AU2015243345A1 (en) 2016-10-13
US20170105960A1 (en) 2017-04-20
KR20160143731A (ko) 2016-12-14
EA201692018A1 (ru) 2017-04-28
WO2015155230A1 (fr) 2015-10-15
CA2944560A1 (fr) 2015-10-15
SG11201607903UA (en) 2016-10-28
IL247903A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MX2016012752A (es) Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp).
MX378072B (es) Nuevos compuestos de succinato permeables a la celula.
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
CR20160553A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
MX2017014351A (es) Un proceso para la preparacion de epoxido de terpinoleno.
MX2018014114A (es) Derivados del sobetiroma.
MY186789A (en) Cathode assembly for the production of aluminum
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
NZ711192A (en) Process for making benzoxazepin compounds
MX2017014662A (es) Proceso nuevo para la eterificacion de las bis-resorcinil triazinas.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IN2013MU01113A (fr)
MX375977B (es) Proceso para preparar 3-metilciclopentadecano-1, 5-diol.
IN2014CH00304A (fr)
CL2018002149A1 (es) Proceso.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
IN2013MU01290A (fr)
CL2020001612A1 (es) Mezclas estables al almacenamiento
CO7141428A2 (es) Proceso para la elaboración de undecapéptidos cíclicos
CL2020001653A1 (es) Mezclas estables al almacenamiento